Ligand Pharmaceuticals (LGND)

• Market cap: $2.04B
• 1 day: -3.21%
• 5 days: -8.33%
• 1 month: -6.19%
• 3 months: -12.11%
• 6 months: 2.62%
• Year to date: -2.43%
• 1 year: 46.42%
• 5 years: 15.20%
• 10 years: 44.84%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Employees: 68

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

527% more call options, than puts

Call options by funds: $3.56M | Put options by funds: $567K

82% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 22

75% more repeat investments, than reductions

Existing positions increased: 105 | Existing positions reduced: 60

8% more capital invested

Capital invested by funds: $1.81B [Q3] → $1.95B (+$140M) [Q4]

5% more funds holding

Funds holding: 239 [Q3] → 251 (+12) [Q4]

2.71% less ownership

Funds ownership: 99.11% [Q3] → 96.4% (-2.71%) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $135 28% upside
• Avg. target: $148 39% upside
• High target: $160 51% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Benchmark Robert Wasserman 36% 1-year accuracy 16 / 45 met price target	28% upside $135	Buy Reiterated	23 Dec 2024
Barclays Balaji Prasad 27% 1-year accuracy 12 / 45 met price target	51% upside $160	Overweight Maintained	16 Dec 2024